|18.43||-0.5800||-3.05%||Vol 47.05K||1Y Perf 29.06%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||-0.02 -0.11%|
|Target Price||56.00||Analyst Rating||Strong Buy 1.33|
|Potential %||203.85||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★ 45.87|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||51.35||Earnings Rating||—|
|Market Cap||548.96M||Earnings Date||13th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th Nov 2023|
|Estimated EPS Next Report||-0.22|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||19.42K|
|Avg. Monthly Volume||7.30K|
|Avg. Quarterly Volume||7.95K|
Calliditas Therapeutics AB (NASDAQ: CALT) stock closed at 18.43 per share at the end of the most recent trading day (a -3.05% change compared to the prior day closing price) with a volume of 47.05K shares and market capitalization of 548.96M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 34 people. Calliditas Therapeutics AB CEO is RenÃ©e Aguiar-Lucander.
The one-year performance of Calliditas Therapeutics AB stock is 29.06%, while year-to-date (YTD) performance is 8.41%. CALT stock has a five-year performance of %. Its 52-week range is between 10.82 and 25.64, which gives CALT stock a 52-week price range ratio of 51.35%
Calliditas Therapeutics AB currently has a PE ratio of -7.20, a price-to-book (PB) ratio of 7.11, a price-to-sale (PS) ratio of 15.00, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -38.20%, a ROC of -47.51% and a ROE of -63.16%. The company’s profit margin is -%, its EBITDA margin is -162.60%, and its revenue ttm is $35.94 Million , which makes it $1.21 revenue per share.
Of the last four earnings reports from Calliditas Therapeutics AB, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Calliditas Therapeutics AB’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Calliditas Therapeutics AB is Strong Buy (1.33), with a target price of $56, which is +203.85% compared to the current price. The earnings rating for Calliditas Therapeutics AB stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Calliditas Therapeutics AB has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Calliditas Therapeutics AB has a Buy technical analysis rating based on Technical Indicators (ADX : 8.62, ATR14 : 1.04, CCI20 : 218.32, Chaikin Money Flow : -0.04, MACD : 0.04, Money Flow Index : 60.15, ROC : 14.32, RSI : 58.86, STOCH (14,3) : 77.51, STOCH RSI : 0.82, UO : 50.76, Williams %R : -22.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Calliditas Therapeutics AB in the last 12-months were:
Mon, 21 Aug 2023 11:20 GMT Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.